Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.43
BAYRY's Cash to Debt is ranked higher than
58% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.43 vs. BAYRY: 0.43 )
BAYRY' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.43

Equity to Asset 0.34
BAYRY's Equity to Asset is ranked higher than
52% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. BAYRY: 0.34 )
BAYRY' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.46
Current: 0.34

0.21
0.46
F-Score: 7
Z-Score: 2.73
M-Score: -2.52
WACC vs ROIC
6.74%
13.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 12.27
BAYRY's Operating margin (%) is ranked higher than
80% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.41 vs. BAYRY: 12.27 )
BAYRY' s 10-Year Operating margin (%) Range
Min: -4.21   Max: 12.29
Current: 12.27

-4.21
12.29
Net-margin (%) 8.90
BAYRY's Net-margin (%) is ranked higher than
79% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.06 vs. BAYRY: 8.90 )
BAYRY' s 10-Year Net-margin (%) Range
Min: -4.41   Max: 14.56
Current: 8.9

-4.41
14.56
ROE (%) 17.95
BAYRY's ROE (%) is ranked higher than
92% of the 876 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. BAYRY: 17.95 )
BAYRY' s 10-Year ROE (%) Range
Min: -9.14   Max: 31.97
Current: 17.95

-9.14
31.97
ROA (%) 6.64
BAYRY's ROA (%) is ranked higher than
83% of the 909 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.17 vs. BAYRY: 6.64 )
BAYRY' s 10-Year ROA (%) Range
Min: -3.18   Max: 8.79
Current: 6.64

-3.18
8.79
ROC (Joel Greenblatt) (%) 29.67
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.06 vs. BAYRY: 29.67 )
BAYRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6.12   Max: 34.99
Current: 29.67

-6.12
34.99
Revenue Growth (3Y)(%) 4.60
BAYRY's Revenue Growth (3Y)(%) is ranked higher than
70% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. BAYRY: 4.60 )
BAYRY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.6   Max: 14
Current: 4.6

-10.6
14
EBITDA Growth (3Y)(%) 2.40
BAYRY's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.50 vs. BAYRY: 2.40 )
BAYRY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.7   Max: 18.3
Current: 2.4

-17.7
18.3
EPS Growth (3Y)(%) 35.00
BAYRY's EPS Growth (3Y)(%) is ranked higher than
90% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. BAYRY: 35.00 )
BAYRY' s 10-Year EPS Growth (3Y)(%) Range
Min: -19.1   Max: 41.4
Current: 35

-19.1
41.4
» BAYRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BAYRY Guru Trades in Q1 2014

Ken Fisher 270,713 sh (+217.05%)
» More
Q2 2014

BAYRY Guru Trades in Q2 2014

Ken Fisher 2,302,369 sh (+750.48%)
» More
Q3 2014

BAYRY Guru Trades in Q3 2014

Ken Fisher 2,511,364 sh (+9.08%)
» More
Q4 2014

BAYRY Guru Trades in Q4 2014

Ken Fisher 2,493,419 sh (-0.71%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-06-30 Add 750.48%0.6%$126.84 - $144.81 $ 143.484%2302369
Ken Fisher 2014-03-31 Add 217.05%0.06%$128.3 - $142.7 $ 143.486%270713
Ken Fisher 2013-06-30 Add 34.62%0.01%$101 - $112.75 $ 143.4834%84456
Vanguard Health Care Fund 2012-12-31 Reduce -21.2%0.21%$83.28 - $96.38 $ 143.4860%2044656
Ken Fisher 2012-09-30 New Buy0.02%$68.01 - $88.62 $ 143.4886%72838
Ken Fisher 2012-03-31 Sold Out 0.01%$0.04 - $75.15 $ 143.48139%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.00
BAYRY's P/E(ttm) is ranked higher than
83% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.40 vs. BAYRY: 29.00 )
BAYRY' s 10-Year P/E(ttm) Range
Min: 8.67   Max: 36.88
Current: 29

8.67
36.88
Forward P/E 18.15
BAYRY's Forward P/E is ranked higher than
89% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 56.18 vs. BAYRY: 18.15 )
N/A
PE(NRI) 29.00
BAYRY's PE(NRI) is ranked higher than
83% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.90 vs. BAYRY: 29.00 )
BAYRY' s 10-Year PE(NRI) Range
Min: 14.08   Max: 37.24
Current: 29

14.08
37.24
P/B 5.22
BAYRY's P/B is ranked higher than
64% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. BAYRY: 5.22 )
BAYRY' s 10-Year P/B Range
Min: 1.15   Max: 5.22
Current: 5.22

1.15
5.22
P/S 2.58
BAYRY's P/S is ranked higher than
80% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.02 vs. BAYRY: 2.58 )
BAYRY' s 10-Year P/S Range
Min: 0.45   Max: 2.58
Current: 2.58

0.45
2.58
PFCF 35.77
BAYRY's PFCF is ranked higher than
88% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 35.77 )
BAYRY' s 10-Year PFCF Range
Min: 7.28   Max: 107
Current: 35.77

7.28
107
POCF 20.49
BAYRY's POCF is ranked higher than
84% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.72 vs. BAYRY: 20.49 )
BAYRY' s 10-Year POCF Range
Min: 4.24   Max: 20.5
Current: 20.49

4.24
20.5
EV-to-EBIT 22.17
BAYRY's EV-to-EBIT is ranked higher than
84% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.35 vs. BAYRY: 22.17 )
BAYRY' s 10-Year EV-to-EBIT Range
Min: -17.9   Max: 24.6
Current: 22.17

-17.9
24.6
PEG 10.74
BAYRY's PEG is ranked higher than
84% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 10.74 )
BAYRY' s 10-Year PEG Range
Min: 0.6   Max: 5.64
Current: 10.74

0.6
5.64
Shiller P/E 43.80
BAYRY's Shiller P/E is ranked higher than
83% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 220.45 vs. BAYRY: 43.80 )
BAYRY' s 10-Year Shiller P/E Range
Min: 13.54   Max: 50.98
Current: 43.8

13.54
50.98
Current Ratio 1.72
BAYRY's Current Ratio is ranked higher than
62% of the 881 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. BAYRY: 1.72 )
BAYRY' s 10-Year Current Ratio Range
Min: 1   Max: 2.13
Current: 1.72

1
2.13
Quick Ratio 1.18
BAYRY's Quick Ratio is ranked higher than
61% of the 881 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. BAYRY: 1.18 )
BAYRY' s 10-Year Quick Ratio Range
Min: 0.64   Max: 1.44
Current: 1.18

0.64
1.44
Days Inventory 136.84
BAYRY's Days Inventory is ranked higher than
73% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 149.40 vs. BAYRY: 136.84 )
BAYRY' s 10-Year Days Inventory Range
Min: 126.63   Max: 174.79
Current: 136.84

126.63
174.79
Days Sales Outstanding 80.83
BAYRY's Days Sales Outstanding is ranked higher than
74% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.21 vs. BAYRY: 80.83 )
BAYRY' s 10-Year Days Sales Outstanding Range
Min: 64.79   Max: 79.65
Current: 80.83

64.79
79.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.47
BAYRY's Dividend Yield is ranked higher than
70% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. BAYRY: 1.47 )
BAYRY' s 10-Year Dividend Yield Range
Min: 1.5   Max: 3.93
Current: 1.47

1.5
3.93
Dividend Payout 0.34
BAYRY's Dividend Payout is ranked higher than
79% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. BAYRY: 0.34 )
BAYRY' s 10-Year Dividend Payout Range
Min: 0.98   Max: 2.85
Current: 0.34

0.98
2.85
Dividend growth (3y) 10.70
BAYRY's Dividend growth (3y) is ranked higher than
84% of the 350 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. BAYRY: 10.70 )
BAYRY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 34.9
Current: 10.7

0
34.9
Yield on cost (5-Year) 2.07
BAYRY's Yield on cost (5-Year) is ranked higher than
81% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. BAYRY: 2.07 )
BAYRY' s 10-Year Yield on cost (5-Year) Range
Min: 2.21   Max: 5.8
Current: 2.07

2.21
5.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.88
BAYRY's Price/DCF (Projected) is ranked higher than
89% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.88 vs. BAYRY: 1.88 )
BAYRY' s 10-Year Price/DCF (Projected) Range
Min: 0.71   Max: 2.05
Current: 1.88

0.71
2.05
Price/Median PS Value 2.06
BAYRY's Price/Median PS Value is ranked higher than
60% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. BAYRY: 2.06 )
BAYRY' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 3.67
Current: 2.06

0.25
3.67
Price/Peter Lynch Fair Value 5.43
BAYRY's Price/Peter Lynch Fair Value is ranked higher than
88% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 5.43 )
BAYRY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.7   Max: 5.19
Current: 5.43

0.7
5.19
Earnings Yield (Greenblatt) 4.50
BAYRY's Earnings Yield (Greenblatt) is ranked higher than
84% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BAYRY: 4.50 )
BAYRY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.1   Max: 13.9
Current: 4.5

4.1
13.9
Forward Rate of Return (Yacktman) 8.50
BAYRY's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.66 vs. BAYRY: 8.50 )
BAYRY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.5   Max: 31.6
Current: 8.5

8.5
31.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BAYN.Germany, BAYA.Germany, BAY.Italy, BAY.Spain, BAYN N.Mexico, BAYN.Switzerland,
Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third-largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing extensive customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Ken Fisher for Forbes - 5 Fantastic Stocks for Fretters Jun 26 2013 
Pfizer: A Strong Stock for 2013 Apr 20 2012 
Maxygen Inc. (MAXY): A Magic Formula Stock to Avoid Feb 05 2009 

More From Other Websites
Cardinal Health (CAH) Tops Q2 Earnings on Strong Revenues - Analyst Blog Jan 29 2015
ETFs Moving On Greek Election Jan 26 2015
Bayer Announces Updates to European Label of Xarelto - Analyst Blog Jan 21 2015
Bayer CropScience offers growers innovative solution with outstanding safety profile: -- New... Jan 20 2015
Barclays Issues 3 Upgrades, 1 Downgrade On Pharma Stocks Jan 16 2015
Bayer MaterialScience optimizes polyurethane systems for automotive clearcoats -- Fast curing,... Jan 15 2015
Efficient application of flexible floor coatings -- New raw materials from Bayer open up further... Jan 15 2015
New milestones in polyurethanes Jan 15 2015
Merck seeks new OK for cancer drug, reorganization on track Jan 12 2015
Merck seeks new OK for cancer drug, reorganization on track Jan 12 2015
Webasto supplys first panorama roof with infrared absorption -- A heat-absorbing panorama roof made... Jan 12 2015
3 Stocks to Benefit From Weakest Euro vs. Dollar Since 2010 Jan 02 2015
Bayer to divest equine assets to Merial -- Divestiture includes Legend® /Hyonate® (hyaluronate... Dec 17 2014
ISIS Jumps on Positive Results for Venous Thrombosis Drug Dec 09 2014
Bayer and DNDi Sign First Agreement to Develop an Innovative Oral Treatment for Human River... Dec 09 2014
Inauguration of the TDI-plant Dormagen -- Address by André van Broich -- Chairman of the Works... Dec 09 2014
Inauguration of the TDI-plant Dormagen -- Adress by Dr. Marijn Dekkers -- Chairman of the Board of... Dec 09 2014
Inauguration of the TDI-plant Dormagen -- Adress by Patrick Thomas -- Chairman of the Board of... Dec 09 2014
Bayer Files Hemophilia A Drug Marketing Application in EU Dec 05 2014
Regeneron at 52-Week High on Eylea Priority Review Status Dec 04 2014
Moody's: Deutsche Anleihe-Emissionen dürften langsamen Wachstumstrend 2015 fortsetzen Dec 03 2014
Actelion Submits Marketing Application for Uptravi in EU Dec 03 2014
Bee health magazine “BEENOW” launched at Bayer’s Perspective on Innovation 2014: -- Partnering... Dec 03 2014
Regeneron/Bayer's Eylea to be Reviewed on a Priority Basis Dec 02 2014
Press Forum: “Bayer’s Perspective on Innovation 2014” -- Address by Kemal Malik -- Member of... Dec 02 2014
Press Forum: “Bayer’s Perspective on Innovation 2014” -- Address by Dr. Marijn Dekkers --... Dec 02 2014
Life science company Bayer steps up focus on research and development Dec 02 2014
An Eye on the Heavens Nov 29 2014
Bayer CropScience opens Weed Resistance Competence Center in Frankfurt, Germany -- Major step... Nov 20 2014
Regeneron/Bayer's Eylea Gets Japanese Approval for DME Nov 19 2014
Sanofi's Lemtrada Gets U.S. Approval, Carries Boxed Warning Nov 17 2014
Dr. Klaus Schäfer to assume new position January 1, 2015 -- New head of Industrial Operations at... Nov 12 2014
Joint venture doubles production capacity for EUR 50 million: -- New plant for plastics component in... Nov 10 2014
Jazz Q3 Tops On Defitelio But Regeneron Cuts View Nov 04 2014
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance Nov 04 2014
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter Nov 04 2014
Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up Nov 03 2014
Not intended for U.S. and UK Media -- Bayer HealthCare to invest up to USD 25 million in “Versant... Nov 03 2014
Bayer MaterialScience at Compamed 2014 -- New material combination for modern wound dressings --... Nov 03 2014
Not intended for U.S. and UK Media -- Bayer completes acquisition of Dihon Pharmaceutical Group Co.,... Nov 03 2014
ARK Investment Adds Genomics, Innovation ETFs Oct 31 2014
Will Regeneron (REGN) Q3 Earnings be Hit by Higher Costs? Oct 30 2014
Bayer to split off polymer division with IPO Sep 18 2014
Pfizer raises offer, highlighting flurry of deals May 19 2014
Boston Scientific to spend $415M on Bayer division May 15 2014
Bayer sells division to Boston Scientific May 15 2014
Merck makes deal worth at least $600M with Santen May 13 2014
Merck: New drugs pending approval or in late tests May 06 2014
Bayer to buy Merck consumer business for $14.2B May 06 2014
Bayer, Merck combining their medicine cabinets May 06 2014
Germany's Bayer to buy Merck consumer business May 06 2014
Bayer reports $4.35 billion full-year net profit Feb 28 2014
Bayer clotting drug meets late-stage study's goal Feb 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK